Published in Psychiatry Res on February 09, 1998
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56
The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci (2010) 0.95
Genetics of obsessive-compulsive disorder. Psychiatr Clin North Am (2010) 0.90
The genetic studies of obsessive-compulsive disorder and its future directions. Yonsei Med J (2006) 0.80
Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Clinics (Sao Paulo) (2012) 0.78
The Genetics of Obsessive-Compulsive Disorder. Curr Psychiatry Rev (2010) 0.77
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry (1998) 3.07
A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry (2001) 1.56
Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis (2001) 1.46
[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry (1995) 1.23
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol (2000) 1.17
The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord (1999) 1.17
Decision-making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia (2002) 1.15
Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol (2001) 1.09
Disorganization of anatomical connectivity in obsessive compulsive disorder: a multi-parameter diffusion tensor imaging study in a subpopulation of patients. Neurobiol Dis (2009) 1.05
Potential toxicity of mitomycin C. Arch Ophthalmol (1991) 1.04
Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry (1995) 1.02
Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry (1999) 1.02
The cooccurrence of DSM-III-R personality disorders. J Pers Disord (1998) 1.01
Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet (1999) 0.98
CO2-induced panic attacks: a twin study. Am J Psychiatry (1998) 0.96
Age at onset of panic disorder: influence of familial liability to the disease and of childhood separation anxiety disorder. Am J Psychiatry (1995) 0.96
Temperament dimensions explain the comorbidity of psychiatric disorders. Compr Psychiatry (1996) 0.94
Factors associated with non-participation of women in a breast cancer screening programme in a town in northern Italy. J Epidemiol Community Health (1991) 0.94
Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry (2000) 0.93
The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res (1998) 0.93
First-cycle REM density in never-depressed subjects with borderline personality disorder. Biol Psychiatry (1999) 0.93
Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry (1997) 0.92
Familial Jarcho-Levin syndrome. Clin Genet (1991) 0.91
Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res (1995) 0.90
Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol (1997) 0.88
Ambulatory polysomnography of never-depressed borderline subjects: a high-risk approach to rapid eye movement latency. Biol Psychiatry (1993) 0.87
Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Am J Psychiatry (1996) 0.87
An experimental test of new theoretical models for the electrokinetic properties of biological membranes. The effect of UO2++ and tetracaine on the electrophoretic mobility of bilayer membranes and human erythrocytes. J Gen Physiol (1986) 0.87
A family study of schizotypal disorder. Schizophr Bull (1995) 0.86
Asthma and panic attacks. Biol Psychiatry (1997) 0.86
Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter (2007) 0.86
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol (1998) 0.86
Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet (1997) 0.86
The 5-HT(2A) -1438G/A polymorphism in anorexia nervosa: a combined analysis of 316 trios from six European centres. Mol Psychiatry (2002) 0.85
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J (2002) 0.85
Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology (2001) 0.85
An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Res (2000) 0.85
Plasma interleukin-1 beta concentrations in panic disorder. Psychiatry Res (1994) 0.85
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2004) 0.84
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.84
Panic disorder: the role of the balance system. J Psychiatr Res (2001) 0.84
Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol Alcohol (1998) 0.84
Obsessive compulsive disorder and mood disorders: a family study. Am J Med Genet (1995) 0.84
Vestibular testing in patients with panic disorder and chronic dizziness. Acta Otorhinolaryngol Ital (2007) 0.84
Laboratory response of patients with panic and obsessive-compulsive disorders to 35% CO2 challenges. Am J Psychiatry (1995) 0.84
Frontal lobe dysfunction in schizophrenia and obsessive-compulsive disorder: a neuropsychological study. Brain Cogn (1995) 0.83
Complex segregation analysis of obsessive-compulsive disorder in 141 families of eating disorder probands, with and without obsessive-compulsive disorder. Am J Med Genet (2000) 0.83
Physiological and behavioral responses to minor stressors in offspring of patients with panic disorder. J Psychiatr Res (1997) 0.83
EEG power modifications in panic disorder during a temporolimbic activation task: relationships with temporal lobe clinical symptomatology. J Neuropsychiatry Clin Neurosci (1993) 0.83
Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene. Psychiatr Genet (1995) 0.83
Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry (1996) 0.83
Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res (1994) 0.82
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2001) 0.82
The 35% CO2 challenge test in patients with social phobia. Psychiatry Res (1997) 0.81
Frontal lobe dysfunction in obsessive-compulsive disorder and major depression: a clinical-neuropsychological study. Psychiatry Res (1998) 0.81
Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol (1997) 0.81
Menstrual cycle-related sensitivity to 35% CO2 in panic patients. Biol Psychiatry (1995) 0.81
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet (2004) 0.81
Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. Psychiatry Res (1999) 0.81
Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. Psychol Med (2010) 0.80
Liver involvement in white patients with sickle-cell disease. Arch Pediatr Adolesc Med (1996) 0.80
Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry (1999) 0.80
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol (1997) 0.80
Personality features related to generalized anxiety disorder. Compr Psychiatry (1990) 0.80
Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.80
MHPG, amitriptyline and affective disorders. A longitudinal study. Int Pharmacopsychiatry (1976) 0.80
Panic attacks: a twin study. Psychiatry Res (1997) 0.80
Dizziness, migrainous vertigo and psychiatric disorders. J Laryngol Otol (2009) 0.79
Abstracts of the 6th FECS Conference 1998 Lectures. Environ Sci Pollut Res Int (1998) 0.79
Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry (1999) 0.79
The HLA system and the clinical response to treatment with chlorpromazine. Br J Psychiatry (1976) 0.79
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. Int J Psychophysiol (1989) 0.79
Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am J Med Genet (1994) 0.79
Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry (1997) 0.79
Relationship between obsessive-compulsive personality disorder and obsessive-compulsive disorder. Compr Psychiatry (1997) 0.79
Psychiatric disorders in the families of schizotypal subjects. Schizophr Bull (1991) 0.78
A psychometric-genetic study of schizotypal disorder. Schizophr Res (1999) 0.78
A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Artif Intell Med (2001) 0.78
A neuropsychological study of dissociation in cortical and subcortical functioning in obsessive-compulsive disorder by Tower of Hanoi task. Brain Cogn (2001) 0.78
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.78
Follow-up of obsessive-compulsive patients treated with proserotonergic agents. J Clin Psychopharmacol (1995) 0.78
An investigation of the co-occurrence of panic and somatization disorders through temperamental variables. Psychosom Med (1999) 0.78
Human nuclear transcription factor gene CREM: genomic organization, mutation screening, and association analysis in panic disorder. Am J Med Genet B Neuropsychiatr Genet (2003) 0.78
Dopamine receptor D4 gene is not associated with major psychoses. Am J Med Genet (1999) 0.78
Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. J Psychiatr Res (1996) 0.78
The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews. Schizophr Bull (1997) 0.78
Anticipation of age at onset in panic disorder. Am J Psychiatry (1998) 0.77
Polymorphic MAO-A and 5-HT-transporter genes: analysis of interactions in panic disorder. World J Biol Psychiatry (2000) 0.77
Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs (2004) 0.77